Sanofi SA vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.69. The key difference: Sanofi SA pays a 5.5% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals.
| SNY | VNQI | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | — |
52-Week High | $52.34 | $50.76 |
52-Week Low | $41.33 | $43.26 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →